Table 3 Overall survival and progression-free survival at 6 and 12 months compared between the 2019 and 2020 cohorts of Patients with WHO Grade 4 gliomas according to Kaplan–Meier estimation.

From: Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations

WHO 4

Treatment year

P

Total

2019

2020

OS-6 (n; %)

140 (75.2)

78 (74.0)

62 (76.6)

.219

OS-12 (n; %)

97 (54.9)

55 (48.0)

42 (66.3)

.058

PFS-6 (n; %)

140 (88.9)

78 (90.5)

62 (86.9)

.426

PFS-12 (n; %)

97 (51.7)

54 (56.6)

43 (43.9)

.095

  1. OS—overall survival, PFS—progression-free survival, n—number.
Back to article page